Genmedica Therapeutics S.L.   Report issue

For profit Phase 1
Founded: Barcelona Spain (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2012
NCT02686281
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

gmc-252-l-lysine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1